811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical reported first-quarter 2025 revenue of $355.4 million, up 9.8%, and non-GAAP EPS of $0.86, up 14.8%. It kept its 2025 net sales guidance unchanged but lowered its 2025 non-GAAP EPS guidance, citing the projected impact of recently implemented trade policies, which matters to shareholders because it reduces expected full-year earnings even as first-quarter results beat expectations.
Q1 2025 net sales of $355.4 million, up 9.8% from $323.5 million a year earlier; GAAP net income of $30.1 million, or $0.49 per diluted share, versus $0.48 a year earlier
Non-GAAP EPS of $0.86 in Q1 2025, versus $0.75 in Q1 2024
2025 non-GAAP EPS guidance lowered to $3.29 to $3.42 from $3.58 to $3.70, citing trade policies
2025 net sales guidance reaffirmed at $1.470 billion to $1.490 billion
MarineMax reported fiscal second-quarter 2025 results for the period ended March 31, 2025, with record revenue of $631.5 million, up 8.3% year over year, and net income of $3.3 million, or $0.14 per diluted share, versus $1.6 million, or $0.07, a year earlier. The company lowered its fiscal 2025 adjusted EPS and adjusted EBITDA guidance, citing tariff-related uncertainty and a slowdown in new sales since early April, which matters to shareholders because it reduces the earnings outlook even as current results improved.
Q2 revenue rose 8.3% to $631.5 million from $582.9 million; gross profit margin fell to 30.0% from 32.7%.
Net income was $3.3 million, or $0.14 per diluted share, compared with $1.6 million, or $0.07, in the prior-year quarter.
Fiscal 2025 adjusted EPS guidance cut to $1.40 to $2.40 from $1.80 to $2.80; adjusted EBITDA guidance cut to $140 million to $170 million from $150 million to $180 million.
CEO Brett McGill said the level of new sales has slowed since the start of April, citing consumer concern about tariffs.
West Pharmaceutical Services reported first-quarter 2025 net sales of $698.0 million, up 0.4%, but adjusted-diluted EPS fell to $1.45 from $1.56 a year earlier. The company raised its full-year 2025 net sales and adjusted-diluted EPS guidance and declared a third-quarter dividend of $0.21 per share, so shareholders see higher expected results for the year alongside weaker first-quarter profit.
Q1 2025 net sales were $698.0 million, up 0.4%; organic net sales grew 2.1%.
Reported-diluted EPS was $1.23 versus $1.55 a year earlier; adjusted-diluted EPS was $1.45 versus $1.56.
Full-year 2025 net sales guidance rose to $2.945 billion-$2.975 billion from $2.875 billion-$2.905 billion.
Full-year 2025 adjusted-diluted EPS guidance rose to $6.15-$6.35 from $6.00-$6.20; the guidance includes an estimate of $20 million to $25 million in tariff costs.
Tractor Supply reported first-quarter 2025 net sales up 2.1% to $3.47 billion, but comparable store sales fell 0.9% and diluted EPS dropped 8.0% to $0.34. The company lowered its full-year 2025 earnings per share range to $2.00 to $2.18 from $2.10 to $2.22, citing new tariffs and increased market uncertainty.
Q1 net sales rose 2.1% to $3.47 billion; comparable store sales decreased 0.9%
Net income fell 9.5% to $179.4 million; diluted EPS was $0.34 versus $0.37 a year earlier
FY2025 EPS guidance cut to $2.00 to $2.18 from $2.10 to $2.22; net sales growth range raised to 4% to 8% from 5% to 7%
Q2 2025 guidance: EPS of $0.79 to $0.81 and comparable store sales flat to up 1%
L3Harris reported first quarter 2025 revenue of $5.1 billion, down 2% from a year earlier, and diluted EPS of $2.04, up from $1.48. It lowered its 2025 non-GAAP diluted EPS guidance to $10.30 to $10.50 from $10.55 to $10.85 and cut its revenue guidance to $21.4 billion to $21.7 billion, citing the completed sale of its Commercial Aviation Solutions business. The company repurchased $569 million of shares in the quarter.
Q1 revenue was $5.1 billion, down 2% from $5.2 billion; organic revenue was flat.
Q1 diluted EPS was $2.04 versus $1.48; non-GAAP diluted EPS was $2.41, up 7%.
2025 non-GAAP diluted EPS guidance cut to $10.30 to $10.50 from $10.55 to $10.85; the CAS divestiture accounts for about $0.55 of the change.
2025 revenue guidance lowered to $21.4 billion to $21.7 billion from $21.8 billion to $22.2 billion.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.